Charles Schwab Investment Management Inc. Reduces Holdings in LeMaitre Vascular, Inc. $LMAT

Key Points

• Charles Schwab Investment Management Inc. decreased its stake in LeMaitre Vascular by 4.7%, selling 9,163 shares and retaining about 186,589 shares valued at $15.65 million.
• LeMaitre Vascular's stock has been rated with a consensus of "Hold" and an average target price of $97.60, with analysts forecasting continued growth.
• The company recently announced a quarterly dividend of $0.20 per share, set to be paid on September 4th, representing a yield of 0.8%.

Charles Schwab Investment Management Inc. decreased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 186,589 shares of the medical instruments supplier's stock after selling 9,163 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.83% of LeMaitre Vascular worth $15,655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of LMAT. GAMMA Investing LLC raised its holdings in LeMaitre Vascular by 7,486.5% during the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock valued at $4,519,000 after acquiring an additional 53,154 shares during the period. Millennium Management LLC raised its holdings in LeMaitre Vascular by 96.8% during the 4th quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier's stock valued at $8,853,000 after acquiring an additional 47,250 shares during the period. Dividend Assets Capital LLC purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at $3,877,000. Monashee Investment Management LLC purchased a new position in shares of LeMaitre Vascular during the 4th quarter valued at $3,686,000. Finally, Marshall Wace LLP grew its position in shares of LeMaitre Vascular by 1,530.6% during the 4th quarter. Marshall Wace LLP now owns 39,786 shares of the medical instruments supplier's stock valued at $3,666,000 after purchasing an additional 37,346 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded down $0.41 during trading hours on Thursday, reaching $95.27. 130,646 shares of the stock traded hands, compared to its average volume of 222,437. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The stock has a 50 day simple moving average of $87.13 and a two-hundred day simple moving average of $86.41. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The company has a market cap of $2.16 billion, a price-to-earnings ratio of 46.25, a price-to-earnings-growth ratio of 2.46 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. The company's revenue was up 15.0% compared to the same quarter last year. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 annualized dividend and a yield of 0.8%. LeMaitre Vascular's payout ratio is 38.83%.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company's stock, valued at $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the sale, the director directly owned 2,916 shares of the company's stock, valued at approximately $274,104. This trade represents a 46.16% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on LMAT shares. Cantor Fitzgerald boosted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $97.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.